Memantine in Patients With Chronic Glaucoma

This study has been completed.

Sponsor:

Information provided by:

Allergan

ClinicalTrials.gov Identifier:

NCT00168350

First received: September 9, 2005

Last updated: November 3, 2010

Last verified: November 2010

History of Changes

Purpose

Randomized double-masked clinical trial of memantine in patients with glaucoma

Condition	Intervention	Phase
Open-Angle Glaucoma	Drug: memantine	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment

Resource links provided by NLM:

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Glaucoma

Drug Information available for: Memantine Memantine hydrochloride

Genetic and Rare Diseases Information Center resources: Pigment-dispersion Syndrome

U.S. FDA Resources

Further study details as provided by Allergan:

Primary Outcome Measures:

Progression of glaucoma


Enrollment:	1179
Study Start Date:	March 2000
Study Completion Date:	September 2006
Primary Completion Date:	September 2006 (Final data collection date for primary outcome measure)

Eligibility


Ages Eligible for Study:	18 Years to 82 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

glaucoma damage on examination of visual field and optic disc
good visual acuity (with glasses if needed)

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided

More Information


ClinicalTrials.gov Identifier:	NCT00168350 History of Changes
Other Study ID Numbers:	192944-005
Study First Received:	September 9, 2005
Last Updated:	November 3, 2010

Additional relevant MeSH terms:


Glaucoma Glaucoma, Open-Angle Ocular Hypertension Eye Diseases Memantine Antiparkinson Agents Anti-Dyskinesia Agents	Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents

ClinicalTrials.gov processed this record on July 17, 2017

To Top